Keryx Biopharmaceuticals (NASDAQ:KERX) announced its earnings results on Thursday. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.15) by $0.01, MarketWatch Earnings reports. The business had revenue of $28.04 million for the quarter, compared to analysts’ expectations of $29.56 million.
Shares of Keryx Biopharmaceuticals stock traded up $0.21 on Friday, hitting $3.24. 3,342,206 shares of the company traded hands, compared to its average volume of 879,466. Keryx Biopharmaceuticals has a 52 week low of $2.74 and a 52 week high of $5.98. The company has a market capitalization of $359.92 million, a PE ratio of -3.68 and a beta of 2.46.
An institutional investor recently raised its position in Keryx Biopharmaceuticals stock. Bank of New York Mellon Corp grew its stake in shares of Keryx Biopharmaceuticals (NASDAQ:KERX) by 10.7% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,056,811 shares of the biopharmaceutical company’s stock after acquiring an additional 102,014 shares during the period. Bank of New York Mellon Corp owned about 0.88% of Keryx Biopharmaceuticals worth $3,974,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 59.41% of the company’s stock.
Several research analysts have issued reports on the company. Maxim Group restated a “hold” rating on shares of Keryx Biopharmaceuticals in a research report on Friday. Zacks Investment Research upgraded Keryx Biopharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, September 10th. BidaskClub lowered Keryx Biopharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Thursday, September 13th. HC Wainwright set a $9.00 target price on Keryx Biopharmaceuticals and gave the company a “buy” rating in a research report on Thursday, August 23rd. Finally, Citigroup dropped their target price on Keryx Biopharmaceuticals from $4.75 to $4.00 and set a “neutral” rating for the company in a research report on Thursday, August 9th. One analyst has rated the stock with a sell rating, six have given a hold rating and one has given a buy rating to the company’s stock. Keryx Biopharmaceuticals presently has a consensus rating of “Hold” and an average price target of $6.25.
ILLEGAL ACTIVITY NOTICE: This article was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright law. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2018/11/10/keryx-biopharmaceuticals-kerx-releases-quarterly-earnings-results.html.
Keryx Biopharmaceuticals Company Profile
Keryx Biopharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on providing medicines for patients with kidney disease in the United States. It markets its lead product Auryxia (ferric citrate), an orally available, absorbable, iron-based medicine for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis, as well as for the treatment of iron deficiency anemia in adults with CKD not on dialysis.
Featured Story: Index Funds
Receive News & Ratings for Keryx Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.